StocksMedium•7 October 2026•
1 min read
Ultragenyx Sells FDA Priority Review Voucher for $210 Million
Key Facts
1Ultragenyx entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million.
2The company received the voucher following FDA approval of GENGLYCOS for the treatment of glycogen storage disease type Ia.
Ultragenyx Pharmaceutical entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million in cash. GlobeNewswire reported that the company received the voucher following the U.S. Food and Drug Administration (FDA) approval of GENGLYCOS, the first treatment designed to address the underlying cause of glycogen storage disease type Ia.
The sale provides the company with significant non-dilutive capital to strengthen its balance sheet following the product approval. RARE closed at $14.46 on October 6, 2026, having reached a day high of $14.7 and a low of $14.08 during that session.